pDONR221_SLC35B2 Citations (2)

Originally described in: The RESOLUTE consortium: unlocking SLC transporters for drug discovery.
Superti-Furga G, Lackner D, Wiedmer T, Ingles-Prieto A, Barbosa B, Girardi E, Goldmann U, Gurtl B, Klavins K, Klimek C, Lindinger S, Lineiro-Retes E, Muller AC, Onstein S, Redinger G, Reil D, Sedlyarov V, Wolf G, Crawford M, Everley R, ... Steppan CM Nat Rev Drug Discov. 2020 Jul;19(7):429-430. doi: 10.1038/d41573-020-00056-6. PubMed Journal

---

Articles Citing pDONR221_SLC35B2

Articles
Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Dieter SM, Lovecchio D, Pataskar A, Zowada MK, Korner PR, Khalizieva A, van Tellingen O, Jager D, Glimm H, Agami R. Oncogene. 2022 Aug;41(32):3953-3968. doi: 10.1038/s41388-022-02400-z. Epub 2022 Jul 7. PubMed
Advancing drug discovery through assay development: a survey of tool compounds within the human solute carrier superfamily. Digles D, Ingles-Prieto A, Dvorak V, Mocking TAM, Goldmann U, Garofoli A, Homan EJ, Di Silvio A, Azzollini L, Sassone F, Fogazza M, Barenz F, Pommereau A, Zuschlag Y, Ooms JF, Tranberg-Jensen J, Hansen JS, Stanka J, Sijben HJ, Batoulis H, Bender E, Martini R, IJzerman AP, Sauer DB, Heitman LH, Manolova V, Reinhardt J, Ehrmann A, Leippe P, Ecker GF, Huber KVM, Licher T, Scarabottolo L, Wiedmer T, Superti-Furga G. Front Pharmacol. 2024 Jul 9;15:1401599. doi: 10.3389/fphar.2024.1401599. eCollection 2024. PubMed

If you have published an article using this material, please email us at to have your article added to this page.